drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
An autologous, CD19-directed CAR T-cell therapy in which patient T cells are genetically engineered to express a CAR with 4-1BB costimulatory and CD3ζ signaling domains; upon CD19 binding, the cells activate, expand, and mediate cytotoxic killing of CD19+ malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Relmacabtagene Autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti‑CD19 CAR with 4‑1BB costimulatory and CD3ζ signaling domains; upon CD19 binding they activate, proliferate, and mediate cytotoxic killing of CD19+ malignant B cells via perforin/granzyme release and cytokine‑driven mechanisms, resulting in on‑target B‑cell depletion.
drug_name
Relmacabtagene autoleucel (Relma-cel; JWCAR029)
nct_id_drug_ref
NCT05806580